Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

ABSTRACT:

Objective

To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years).

Research design and methods

Post hoc analysis of a prospective, interventional, single-arm, multicentre, open-label, 6-month study performed in 233 recently diagnosed and 360 chronic patients.

Main outcome measures

The proportion achieving treatment response (defined as ≥20% improvement in Positive and Negative Syndrome Scale [PANSS] total score from baseline to endpoint) and maintained efficacy (defined as non-inferiority in the change in PANSS total score at endpoint [Schuirmann's test]).

Results

SUBMITTER: Hargarter L 

PROVIDER: S-EPMC4898156 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature